72 related articles for article (PubMed ID: 20708060)
1. Pramipexole for stage 2 treatment-resistant major depression: an open study.
Inoue T; Kitaichi Y; Masui T; Nakagawa S; Boku S; Tanaka T; Suzuki K; Nakato Y; Usui R; Koyama T
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1446-9. PubMed ID: 20708060
[TBL] [Abstract][Full Text] [Related]
2. Pramipexole in treatment-resistant depression: an extended follow-up.
Cassano P; Lattanzi L; Soldani F; Navari S; Battistini G; Gemignani A; Cassano GB
Depress Anxiety; 2004; 20(3):131-8. PubMed ID: 15549689
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
4. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
[TBL] [Abstract][Full Text] [Related]
6. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders.
Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects.
Pae CU; Mandelli L; Kim TS; Han C; Masand PS; Marks DM; Patkar AA; Steffens DC; De Ronchi D; Serretti A
Biomed Pharmacother; 2009 Mar; 63(3):228-35. PubMed ID: 18502089
[TBL] [Abstract][Full Text] [Related]
8. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
9. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
Bares M; Kopecek M; Novak T; Stopkova P; Sos P; Kozeny J; Brunovsky M; Höschl C
J Affect Disord; 2009 Nov; 118(1-3):94-100. PubMed ID: 19249105
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series.
Perugi G; Toni C; Ruffolo G; Frare F; Akiskal H
Pharmacopsychiatry; 2001 Jul; 34(4):137-41. PubMed ID: 11518474
[TBL] [Abstract][Full Text] [Related]
11. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients.
Feighner JP; Sverdlov L; Hlavka J; Nicolau G; Cartwright K; Freed JS
Int Clin Psychopharmacol; 2008 Jan; 23(1):29-35. PubMed ID: 18090505
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
13. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590
[TBL] [Abstract][Full Text] [Related]
14. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women.
Pae CU; Mandelli L; Han C; Ham BJ; Masand PS; Patkar AA; Steffens DC; De Ronchi D; Serretti A
Neuro Endocrinol Lett; 2008 Aug; 29(4):500-6. PubMed ID: 18766158
[TBL] [Abstract][Full Text] [Related]
15. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
Schmitt L; Tonnoir B; Arbus C
Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
[TBL] [Abstract][Full Text] [Related]
17. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
Lee MS; Ham BJ; Kee BS; Kim JB; Yeon BK; Oh KS; Oh BH; Lee C; Jung HY; Chee IS; Choe BM; Paik IH
Curr Med Res Opin; 2005 Sep; 21(9):1369-75. PubMed ID: 16197655
[TBL] [Abstract][Full Text] [Related]
18. An open-label, flexible-dose study of memantine in major depressive disorder.
Ferguson JM; Shingleton RN
Clin Neuropharmacol; 2007; 30(3):136-44. PubMed ID: 17545748
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
20. Pramipexole in treatment-resistant depression: a 16-week naturalistic study.
Lattanzi L; Dell'Osso L; Cassano P; Pini S; Rucci P; Houck PR; Gemignani A; Battistini G; Bassi A; Abelli M; Cassano GB
Bipolar Disord; 2002 Oct; 4(5):307-14. PubMed ID: 12479663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
